Nanjing Leads Biolabs Co., Ltd.
南京维立志博生物科技股份有限公司
(A joint stock company established in the People's Republic of China with limited liability)
(Stock Code: 9887)

VOLUNTARY ANNOUNCEMENT LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) GRANTED FAST TRACK DESIGNATION BY THE U.S. FDA

This announcement is made by Nanjing Leads Biolabs Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform shareholders and potential investors of the Company about the latest business development of the Company.

The Company is pleased to announce that LBL-024 (Opamtistomig), a PD-L1/4-1BB bispecific antibody, was granted Fast Track Designation by the U.S. Food and Drug Administration ("**FDA**") for the treatment of extrapulmonary neuroendocrine carcinoma (EP-NEC) on January 14, 2026.

ABOUT FAST TRACK DESIGNATION

Fast Track Designation is a method granted by the FDA to expedite the review of drugs that treats serious or life-threatening condition or address unmet medical needs to facilitate the development of drugs. It provides several important procedural incentives, including more frequent regulatory communication and guidance from the FDA, as well as the eligibility to submit new drug applications for regulatory approval on a rolling basis.

ABOUT LBL-024 (OPAMTISTOMIG)

LBL-024 is a bispecific antibody simultaneously targeting PD-L1 and 4-1BB. It stands as the first treatment targeting 4-1BB receptor to have reached registrational stage globally for extra-pulmonary neuroendocrine carcinoma (EP-NEC). In Phase II or registrational clinical trials in the three indications of non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC) and EP-NEC, LBL-024 has demonstrated potential for first-in-class (FIC) or best-in-class (BIC) clinical activity. LBL-024 also has the potential to become the first drug approved for treating advanced EP-NEC. Leveraging our self-developed X-body® platform with full intellectual property rights, LBL-024 features an optimal 2:2 structural design and can relieve PD-1/L1 immunosuppression and enhance 4-1BB regulated T-cell activation, achieving a synergistic effect in eliminating tumors and demonstrating greater potential for broad-spectrum cancer treatment compared to PD-1/L1 inhibitors.

In two clinical trials conducted in China, LBL-024 demonstrated encouraging efficacy signals and favorable safety profiles in patients with advanced EP-NEC, both as monotherapy and in combination with chemotherapy. The Company obtained an approval from the National Medical Products Administration (NMPA) for a single-arm registrational trial in April 2024 and received the Breakthrough Therapy Designation (BTD) for LBL-024 in treating late-line advanced EP-NEC from the NMPA in October 2024, the Orphan Drug Designation (ODD) in treating neuroendocrine carcinoma (NEC) from the FDA in November 2024.

4-1BB, as an agonist, can reactivate apoptotic T cells and induce substantial proliferation, making it especially suitable for treating "cold tumors" that are resistant or unresponsive to PD-1/PD-L1 therapies. In addition to EP-NEC, LBL-024 has demonstrated promising clinical signals in multiple tumor types with high unmet medical needs, including SCLC, biliary tract cancer (BTC), ovarian cancer (OC), NSCLC, esophageal squamous cell carcinoma (ESCC), hepatocellular carcinoma (HCC), gastric cancer (GC), triple-negative breast cancer (TNBC) and melanoma. Encouraging clinical results have already been observed in several tumor types such as SCLC, BTC and OC, and the drug is expected to become a promising anti-tumor therapy with broad-spectrum applicability.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will be able to develop, or ultimately market, LBL-024, successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By order of the Board
Nanjing Leads Biolabs Co., Ltd.
南京维立志博生物科技股份有限公司
Dr. KANG XIAOQIANG
Chairman, Executive Director and Chief Executive Officer

Nanjing, PRC, January 14, 2026

As at the date of this announcement, the board of directors of the Company comprises: (i) Dr. Kang Xiaoqiang (Chairman of the Board), Dr. Lai Shoupeng and Mr. Zuo Honggang as executive Directors; (ii) Mr. Zhang Yincheng, Dr. Chen Renhai and Dr. Ni Jia as non-executive Directors; and (iii) Dr. Zhang Hongbing, Mr. Du Yilong and Ms. Du Jiliu as independent non-executive Directors.